A Randomized Trial of Empagliflozin to Increase Plasma Sodium Levels in Patients with the Syndrome of Inappropriate Antidiuresis

BACKGROUND: Treatment options to address the hyponatremia induced by the syndrome of inappropriate antidiuresis (SIAD) are inadequate. The sodium glucose cotransporter 2 (SGLT2) inhibitor empagliflozin promotes osmotic diuresis via urinary glucose excretion and therefore, might offer a novel treatme...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Am Soc Nephrol
Main Authors: Refardt, Julie, Imber, Cornelia, Sailer, Clara O., Jeanloz, Nica, Potasso, Laura, Kutz, Alexander, Widmer, Andrea, Urwyler, Sandrine A., Ebrahimi, Fahim, Vogt, Deborah R., Winzeler, Bettina, Christ-Crain, Mirjam
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Nephrology 2020
Assuntos:
Clinical Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7062212/
https://ncbi.nlm.nih.gov/pubmed/32019783
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2019090944
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados